Gene · 51135
Papers3,419
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 3,419
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IL-1 receptor-associated kinase family proteins: An overview of their role in liver disease. | Eur J Pharmacol | 2024 | 38936453 | PubTator, text mining | PubMed |
| Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma. | J Med Chem | 2024 | 38920289 | PubTator, text mining | PubMed |
| Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury. | J Med Chem | 2024 | 38913701 | PubTator, text mining | PubMed |
| Advances in Targeted Therapies for Inflammatory Diseases and Cancer: Exploring Cellular Mechanisms and Therapeutic Strategies. | ACS Med Chem Lett | 2024 | 38894902 | PubTator, text mining | PubMed |
| Salmonella Osteomyelitis Due to IRAK-4 Deficiency. | J Pediatr Hematol Oncol | 2024 | 38857180 | PubTator, text mining | PubMed |
| Both IRAK3 and IRAK1 Activate the MyD88-TRAF6 Pathway in Zebrafish. | J Immunol | 2024 | 38847613 | PubTator, text mining | PubMed |
| Two novel compound heterozygous loss-of-function mutations cause fetal IRAK-4 deficiency presenting with Pseudomonas Aeruginosa sepsis. | Clin Immunol | 2024 | 38838930 | PubTator, text mining | PubMed |
| Delayed Presentation of IRAK4 Deficiency. | J Clin Immunol | 2024 | 38758474 | PubTator, text mining | PubMed |
| MyD88 Inhibition Attenuates Cerebral Ischemia-reperfusion Injury by Regulating the Inflammatory Response and Reducing Blood-brain Barrier Damage. | Neuroscience | 2024 | 38754722 | PubTator, text mining | PubMed |
| Transforming Therapeutic Approaches with PROTAC Technology: New Targets and Potentials. | ACS Med Chem Lett | 2024 | 38746888 | PubTator, text mining | PubMed |
| [Study of antitumor effects of human placenta hydrolysate on PC-3, OAW-42, BT-474 cell cultures]. | Ter Arkh | 2024 | 38713042 | PubTator, text mining | PubMed |
| Inhibiting the IRAK4/NF-κB/NLRP3 signaling pathway can reduce pyroptosis in hippocampal neurons and seizure episodes in epilepsy. | Exp Neurol | 2024 | 38685307 | PubTator, text mining | PubMed |
| FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. | Curr Issues Mol Biol | 2024 | 38666914 | PubTator, text mining | PubMed |
| Multiplex proteomics identifies inflammation-related plasma biomarkers for aging and cardio-metabolic disorders. | Clin Proteomics | 2024 | 38649851 | PubTator, text mining | PubMed |
| MST1/2 exerts a pivotal role in inducing neuroinflammation and Coxsackievirus-A10 replication by interacting with innate immunity. | Virol J | 2024 | 38641810 | PubTator, text mining | PubMed |
| In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833). | ACS Med Chem Lett | 2024 | 38628800 | PubTator, text mining | PubMed |
| OTUD5 promotes the inflammatory immune response by enhancing MyD88 oligomerization and Myddosome formation. | Cell Death Differ | 2024 | 38605168 | PubTator, text mining | PubMed |
| Oxomollugin, an oxidized substance in mollugin, inhibited LPS-induced NF-κB activation via the suppressive effects on essential activation factors of TLR4 signaling. | J Nat Med | 2024 | 38564154 | PubTator, text mining | PubMed |
| Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients. | Adv Biomed Res | 2024 | 38525404 | PubTator, text mining | PubMed |
| Effects of chronic Cr and Ni co-exposure on liver inflammation and autophagy in mice by regulating the TLR4/mTOR pathway. | Sci Total Environ | 2024 | 38522525 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51135/papers?page=9